Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Girentuximab is a monoclonal antibody that targets G250, an antigen expressed by renal cell carcinoma cells, with potential utility as a carrier for other therapeutic agents (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Girentuximab||Rencarex||WX-G250|chimeric monoclonal antibody cG250||Rencarex (Girentuximab) is a monoclonal antibody that targets G250, an antigen expressed by renal cell carcinoma cells, with potential utility as a carrier for other therapeutic agents (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||no benefit||Girentuximab||Phase III||Actionable||In a Phase III trial, treatment with Girentuximab did not result in a greater disease free survival or overall survival compared to placebo in patients with high risk renal clear cell carcinoma (PMID: 27787547).||27787547|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00717587||Phase II||Sunitinib Girentuximab Motexafin gadolinium||Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer||Unknown status|